Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03466736 · ClinicalTrials.gov registry record

Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects

A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by University of Utah.

Completed
Registry status
165
Enrollment target
1
Study location

NCT03466736: Completed study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by University of Utah.

NCT03466736 is a study of Alzheimer Disease and Mild Cognitive Impairment that has completed, run by University of Utah. The registered enrollment target is 165 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03466736, a study of Alzheimer Disease and Mild Cognitive Impairment, has completed, sponsored by University of Utah.

COMPLETED
Registry status
165 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to demonstrate that individuals with low short-term practice effects (STPE) on cognitive testing are more likely to be identified as "positive" on amyloid imaging than individuals with high STPE. STPE may also inform us about other AD-related biomarkers, including hippocampal volumes, functional connectivity, and APOE status. By realizing the aims of this pragmatic study, we hope to be able to offer more economical and efficient screening of potential participants for clinical trials, which would reduce participant burden and financial costs.

Primary Outcome

Amount of improvement when cognitive tests are repeated twice within one week

Interventions

  • DIAGNOSTIC_TEST [18F]flutemetamol PET scan

Study Locations (1)

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2018-09-01
Est. Completion 2023-04-20
University of Utah

818 total trials

What the finished NCT03466736 record still lists

NCT03466736 is an observational study that tracks outcomes without assigning an intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which [18F]flutemetamol PET scan is the first listed.

NCT03466736 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT03466736 about?

NCT03466736 is a clinical study titled "Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects". The primary objective of this study is to demonstrate that individuals with low short-term practice effects (STPE) on cognitive testing are more likely to be identified as "positive" on amyloid imaging than individuals with high STPE. STPE may also inform us about other AD-related biomarkers, includ...

What is the current status of trial NCT03466736?

This trial is currently completed. The enrollment target is 165 participants. The study started on 2018-09-01. Estimated completion is 2023-04-20.

What conditions does trial NCT03466736 study?

This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment.

What interventions are being tested in trial NCT03466736?

The interventions under investigation include: [18F]flutemetamol PET scan (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03466736?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03466736 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03466736's enrollment target sits among peer trials

165 120th of 306 higher than 186 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02387255 · 165 participants

    Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms

  • NCT03351348 · 165 participants · Phase 3

    Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

  • NCT03830320 · 165 participants · Phase 1

    Positron Emission Tomography (PET) Imaging of Thrombosis

  • NCT04289571 · 165 participants · Phase 1

    Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03466736, the US trial registry maintained by the National Library of Medicine. NCT03466736 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.